DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses - Inria - Institut national de recherche en sciences et technologies du numérique Access content directly
Journal Articles Biometrical Journal Year : 2022

DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses

Abstract

Dose-finding clinical trials in oncology aim to determine the maximum tolerated dose (MTD) of a new drug, generally defined by the proportion of patients with short-term dose-limiting toxicities (DLTs). Model-based approaches for such phase I oncology trials have been widely designed and are mostly restricted to the DLTs occurring during the first cycle of treatment, although patients continue to receive treatment for multiple cycles. We aim to estimate the probability of DLTs over sequences of treatment cycles via a Bayesian cumulative modeling approach, where the probability of DLT is modeled taking into account the cumulative effect of the administered drug and the DLT cycle of occurrence. We propose a design, called DICE (Dose-fInding CumulativE), for dose escalation and de-escalation according to previously observed toxicities, which aims at finding the MTD sequence (MTS). We performed an extensive simulation study comparing this approach to the time-to-event continual reassessment method (TITE-CRM) and a benchmark. In general, our approach achieved a better or comparable percentage of correct MTS selection. Moreover, we investigated the DICE prediction ability.
No file

Dates and versions

hal-03873768 , version 1 (27-11-2022)

Identifiers

Cite

Moreno Ursino, Lucie Biard, Sylvie Chevret. DICE: A Bayesian model for early dose finding in phase I trials with multiple treatment courses. Biometrical Journal, In press, ⟨10.1002/bimj.202000369⟩. ⟨hal-03873768⟩
30 View
0 Download

Altmetric

Share

Gmail Mastodon Facebook X LinkedIn More